Findings

What do systematic reviews say?

101 questions · 108 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 6.5%GRADE not reported 0 · 0%Very low 17 · 15.7%Low 47 · 43.5%Moderate 37 · 34.3%High 0 · 0%

Budesonide vs mesalamine

Clinical improvement · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.98 [0.69, 1.4]
1 study · 247 participants
Moderate

Budesonide vs mesalamine

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.75 [0.17, 3.28]
1 study · 254 participants
Low

Budesonide 6 mg vs budesonide

Remission · Participants with Crohn's disease in remission

Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with budesonide 3 mg (moderate certainty).

3 findings from 1 review

Budesonide for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.07 [0.85, 1.34]
3 studies · 180 participants
Moderate
Budesonide for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.12 [0.85, 1.47]
3 studies · 180 participants
Moderate
Budesonide for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.18 [0.85, 1.65]
3 studies · 180 participants
Moderate

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.12 [0.01, 2.21]
1 study · 55 participants
Low

Budesonide vs placebo

Clinical response sensitivity analysis excluding Miehlke 2014 · Patients with collagenous colitis

Budesonide may leads to higher clinical response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 4.56 [2.43, 8.55]
3 studies · 94 participants
Low

Budesonide vs placebo

Histological response sensitivity analysis excluding Miehlke 2014 · Patients with collagenous colitis

Budesonide may leads to higher histological response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 4.15 [2.25, 7.66]
3 studies · 94 participants
Low

Budesonide vs placebo

Maintenance of clinical response · Patients with collagenous colitis

Budesonide may leads to higher maintenance of clinical response compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 3.3 [2.13, 5.09]
3 studies · 172 participants
Low

Budesonide vs placebo

Maintenance of histological response · Patients with collagenous colitis

It is very uncertain whether budesonide changes maintenance of histological response compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 3.17 [1.44, 6.95]
2 studies · 80 participants
Very low

Budesonide vs placebo

Adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.18 [0.92, 1.51]
5 studies · 290 participants
Low

Budesonide vs placebo

Withdrawals due to adverse events · Patients with collagenous colitis

It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.97 [0.43, 2.17]
5 studies · 290 participants
Very low

Budesonide vs placebo

Serious adverse events · Patients with collagenous colitis

It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.11 [0.15, 8.01]
4 studies · 175 participants
Very low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Clinical response · Patients with collagenous colitis

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.82 [1.13, 2.93]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Histological response · Patients with collagenous colitis

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.97 [1.24, 3.13]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.69 [0.43, 1.1]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.65]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Clinical response · patients with active lymphocytic colitis

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.03 [1.25, 3.33]
2 studies · 57 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Histological response · patients with active lymphocytic colitis

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.44 [1.13, 5.28]
2 studies · 39 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · patients with active lymphocytic colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.59]
1 study · 42 participants
Low

Budesonide vs placebo

Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness

Budesonide may leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
RR 0.37 [0.23, 0.61]
2 studies · 132 participants
Low

Budesonide vs placebo

Incidence of high altitude pulmonary oedema (HAPE)‐ not reported · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found